Clinicopathologic features, management and outcomes of blastoid variant of mantle cell lymphoma: a Nebraska Lymphoma Study Group Experience

References

• A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin’s lymphoma. The Non-Hodgkin’s Lymphoma Classification Project. Blood 1997; 89: 3909–3918.
   PubMed Web of Science ®Google Scholar
• Campo E, Raffeld M, Jaffe ES. Mantle-cell lymphoma. Semin Hematol 1999; 36: 115–127.
   PubMed Web of Science ®Google Scholar
• Weisenburger DD, Armitage JO. Mantle cell lymphoma – an entity comes of age. Blood 1996; 87: 4483–4494.
   PubMed Web of Science ®Google Scholar
• Fisher RI. Mantle-cell lymphoma: classification and therapeutic implications. Ann Oncol 1996; 7(Suppl. 6):S35–39.
   PubMedGoogle Scholar
• Gerard-Marchant R, Hamlin I, Lennert K, et al. Classification of non-Hodgkin’s lymphomas. Lancet 1974; 2: 405–408.
   Web of Science ®Google Scholar
• Harris N, Jaffe E, Stein H, et al. A revised European–American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood 1994; 84: 1361–1392.
   PubMed Web of Science ®Google Scholar
• Swerdlow SH, Campo E, Harris NL, et al. WHO classification of tumours of haematopoietic and lymphoid tissues. Primary mediastinal (thymic) large B-cell lymphoma. Lyon, France: IARC Press; 2008. pp 250–251.
   Google Scholar
• Ahmadi T, McQuade J, Porter D, et al. Potential prolongation of PFS in mantle cell lymphoma after R-HyperCVAD: auto-SCT consolidation or rituximab maintenance. Bone Marrow Transplant 2012; 47: 1082–1086.
   PubMed Web of Science ®Google Scholar
• Geisler CH, Kolstad A, Laurell A, et al. Nordic MCL2 trial update: six-year follow-up after intensive immunochemotherapy for untreated mantle cell lymphoma followed by BEAM or BEAC + autologous stem-cell support: still very long survival but late relapses do occur. Br J Haematol 2012; 158: 355–362.
   PubMed Web of Science ®Google Scholar
• Gressin R, Caulet-Maugendre S, Deconinck E, et al. Evaluation of the (R)VAD + C regimen for the treatment of newly diagnosed mantle cell lymphoma. Combined results of two prospective phase II trials from the French GOELAMS group. Haematologica 2010; 95: 1350–1357.
   PubMed Web of Science ®Google Scholar
• Damon LE, Johnson JL, Niedzwiecki D, et al. Immunochemotherapy and autologous stem-cell transplantation for untreated patients with mantle-cell lymphoma: CALGB 59909. J Clin Oncol 2009; 27: 6101–6108.
   PubMed Web of Science ®Google Scholar
• Dreger P, Rieger M, Seyfarth B, et al. Rituximab-augmented myeloablation for first-line autologous stem cell transplantation for mantle cell lymphoma: effects on molecular response and clinical outcome. Haematologica 2007; 92: 42–49.
   PubMed Web of Science ®Google Scholar
• Gianni AM, Magni M, Martelli M, et al. Long-term remission in mantle cell lymphoma following high-dose sequential chemotherapy and in vivo rituximab-purged stem cell autografting (R-HDS regimen). Blood 2003; 102: 749–755.
   PubMed Web of Science ®Google Scholar
• Visco C, Finotto S, Zambello R, et al. Combination of rituximab, bendamustine, and cytarabine for patients with mantle-cell non-Hodgkin lymphoma ineligible for intensive regimens or autologous transplantation. J Clin Oncol 2013; 31: 1442–1449.
   PubMed Web of Science ®Google Scholar
• Chang JE, Peterson C, Choi S, et al. VcR-CVAD induction chemotherapy followed by maintenance rituximab in mantle cell lymphoma: a Wisconsin Oncology Network study. Br J Haematol 2011; 155: 190–197.
   PubMed Web of Science ®Google Scholar
• Romaguera JE, Fayad LE, Feng L, et al. Ten-year follow-up after intense chemoimmunotherapy with Rituximab-HyperCVAD alternating with Rituximab-high dose methotrexate/cytarabine (R-MA) and without stem cell transplantation in patients with untreated aggressive mantle cell lymphoma. Br J Haematol 2010; 150: 200–208.
   PubMed Web of Science ®Google Scholar
• Belch A, Kouroukis CT, Crump M, et al. A phase II study of bortezomib in mantle cell lymphoma: the National Cancer Institute of Canada Clinical Trials Group trial IND.150. Ann Oncol 2007; 18: 116–121.
   PubMed Web of Science ®Google Scholar
• Majlis A, Pugh WC, Rodriguez MA, et al. Mantle cell lymphoma: correlation of clinical outcome and biologic features with three histologic variants. J Clin Oncol 1997; 15: 1664–1671.
   PubMed Web of Science ®Google Scholar
• Argatoff LH, Connors JM, Klasa RJ, et al. Mantle cell lymphoma: a clinicopathologic study of 80 cases. Blood 1997; 89: 2067–2078.
   PubMed Web of Science ®Google Scholar
• Norton AJ, Matthews J, Pappa V, et al. Mantle cell lymphoma: natural history defined in a serially biopsied population over a 20-year period. Ann Oncol 1995; 6: 249–256.
   PubMed Web of Science ®Google Scholar
• Shrestha R, Bhatt VR, Guru Murthy GS, et al. Clinicopathologic features and management of blastoid variant of mantle cell lymphoma. Leuk Lymphoma 2015. [Epub ahead of print]. doi: 10.3109/10428194.2015.1026902.
   Web of Science ®Google Scholar
• Pott C, Schrader C, Bruggemann M, et al. Blastoid variant of mantle cell lymphoma: late progression from classical mantle cell lymphoma and quantitation of minimal residual disease. Eur J Haematol 2005; 74: 353–358.
   PubMed Web of Science ®Google Scholar
• Raty R, Franssila K, Jansson SE, et al. Predictive factors for blastoid transformation in the common variant of mantle cell lymphoma. Eur J Cancer 2003; 39: 321–329.
   PubMed Web of Science ®Google Scholar
• Bernard M, Gressin R, Lefrere F, et al. Blastic variant of mantle cell lymphoma: a rare but highly aggressive subtype. Leukemia 2001; 15: 1785–1791.
   PubMed Web of Science ®Google Scholar
• Cogliatti SB, Bertoni F, Zimmermann DR, et al. IgV H mutations in blastoid mantle cell lymphoma characterize a subgroup with a tendency to more favourable clinical outcome. J Pathol 2005; 206: 320–327.
   PubMed Web of Science ®Google Scholar
• Ferrer A, Bosch F, Villamor N, et al. Central nervous system involvement in mantle cell lymphoma. Ann Oncol 2008; 19: 135–141.
   PubMed Web of Science ®Google Scholar
• Gill S, Herbert KE, Prince HM, et al. Mantle cell lymphoma with central nervous system involvement: frequency and clinical features. Br J Haematol 2009; 147: 83–88.
   PubMed Web of Science ®Google Scholar
• Conconi A, Franceschetti S, Lobetti-Bodoni C, et al. Risk factors of central nervous system relapse in mantle cell lymphoma. Leuk Lymphoma 2013; 54: 1908–1914.
   PubMed Web of Science ®Google Scholar
• Cheah CY, George A, Gine E, et al. Central nervous system involvement in mantle cell lymphoma: clinical features, prognostic factors and outcomes from the European Mantle Cell Lymphoma Network. Ann Oncol 2013; 24: 2119–2123.
   PubMed Web of Science ®Google Scholar
• Bosch F, Lopez-Guillermo A, Campo E, et al. Mantle cell lymphoma: presenting features, response to therapy, and prognostic factors. Cancer 1998; 82: 567–575.
   PubMed Web of Science ®Google Scholar
• Tiemann M, Schrader C, Klapper W, et al. Histopathology, cell proliferation indices and clinical outcome in 304 patients with mantle cell lymphoma (MCL): a clinicopathological study from the European MCL Network. Br J Haematol 2005; 131: 29–38.
   PubMed Web of Science ®Google Scholar
• Khoury JD, Sen F, Abruzzo LV, et al. Cytogenetic findings in blastoid mantle cell lymphoma. Hum Pathol 2003; 34: 1022–1029.
   PubMed Web of Science ®Google Scholar
• Bea S, Ribas M, Hernandez JM, et al. Increased number of chromosomal imbalances and high-level DNA amplifications in mantle cell lymphoma are associated with blastoid variants. Blood 1999; 93: 4365–4374.
   PubMed Web of Science ®Google Scholar
• Hernandez L, Fest T, Cazorla M, et al. p53 gene mutations and protein overexpression are associated with aggressive variants of mantle cell lymphomas. Blood 1996; 87: 3351–3359.
   PubMed Web of Science ®Google Scholar
• Pinyol M, Hernandez L, Cazorla M, et al. Deletions and loss of expression of p16INK4a and p21Waf1 genes are associated with aggressive variants of mantle cell lymphomas. Blood 1997; 89: 272–280.
   PubMed Web of Science ®Google Scholar
• Gronbaek K, Nedergaard T, Andersen MK, et al. Concurrent disruption of cell cycle associated genes in mantle cell lymphoma: a genotypic and phenotypic study of cyclin D1, p16, p15, p53 and pRb. Leukemia 1998; 12: 1266–1271.
   PubMed Web of Science ®Google Scholar
• Zoldan MC, Inghirami G, Masuda Y, et al. Large-cell variants of mantle cell lymphoma: cytologic characteristics and p53 anomalies may predict poor outcome. Br J Haematol 1996; 93: 475–486.
   PubMed Web of Science ®Google Scholar
• Geisler CH, Kolstad A, Laurell A, et al. Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group. Blood 2008; 112: 2687–2693.
   PubMed Web of Science ®Google Scholar